Prognostic Factors for Survival in Ewing's Sarcoma Identified
the Cancer Therapy Advisor take:
According to a new study published in the journal Cancer Epidemiology, researchers from the University of Iowa Department of Orthopedics and Rehabilitation in Iowa City, Iowa, have identified certain prognostic factors for survival in patients with Ewing's sarcoma.
For the retrospective study, researchers sough to determine cause-specific survival in patients with Ewing's sarcoma and identify clinical risk factors for survival. Researchers identified 1,163 patients with osseous Ewing's sarcoma from the Surveillance, Epidemiology, and End Results (SEER) Program database between 1991 and 2010.
Results showed that the 10-year cause-specific survival for patients with non-metastatic Ewing's sarcoma at the time of diagnosis was 66.8% compared with 28.1% for patients with metastatic disease at diagnosis.
Researchers also found that black patients had decreased survival at 10 years and an increased frequency of metastatic disease at the time of diagnosis compared with other races, and Hispanic patients presented with tumor size greater than 10cm more frequently than other races.
Analyses showed that age ≥20 years, tumor size >10cm, metastatic disease at presentation, and axial tumor location were associated with reduced cause-specific survival at 10 years among patients with Ewing's sarcoma.
Researchers have identified certain prognostic factors for survival in patients with Ewing's sarcoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed